SEARCH

SEARCH BY CITATION

References

  • 1
    Marks JS. The burden of chronic disease and future of public health. CDC Information Sharing Meeting. National Center for Chronic Disease Prevention and Health Promotion, Atlanta, GA, 2003.
  • 2
    Collins R, Armitage J, Parish S, Sleight P, Peto R, Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20 536 people with cerebrovascular disease or other high-risk conditions. Lancet. 2004; 363: 757767.
  • 3
    Gerstein HC. Reduction of cardiovascular events and microvascular complications in diabetes with ACE inhibitor treatment: HOPE and MICRO-HOPE. Diabetes Metab Res Rev. 2011; 18 (Suppl. 3): S8285.
  • 4
    Mehler PS, Coll JR, Estacio R, Esler A, Schrier RW, Hiatt WR. Intensive blood pressure control reduces the risk of cardiovascular events in patients with peripheral arterial disease and type 2 diabetes. Circulation. 2003; 107: 753756.
  • 5
    Mora S, Glynn RJ, Hsia J, MacFadyen JG, Genest J, Riker PM. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: Results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials. Circulation. 2010; 121: 10691077.
  • 6
    ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): A randomised controlled trial. Lancet. 2007; 37: 829840.
  • 7
    Taylor F, Ward K, Moore TH et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2011; 1 : CD004816.
  • 8
    van Vark LC, Bertrand M, Akkerhuis KM et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: A meta-analysis of randomized clinical trials of renin–angiotensin–aldosterone system inhibitors involving 158 998 patients. Eur Heart J. 2012; 33: 20882097.
  • 9
    Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000; 342: 145153.
  • 10
    Knowler WC, Barrett-Connor E, Fowler SE et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002; 346: 393403.
  • 11
    Chiasson JL, Josee RG, Gomis R et al. Acarbose for prevention of type 2 diabetes mellitus: The STOP-NIDDM randomized trial. Lancet. 2002; 259: 20722077.
  • 12
    DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: A randomised controlled trial. Lancet. 2006; 368: 10961105.
  • 13
    Kardas P. Rozpowszechnienie nieprzestrzegania zalecen terapeutycznych wsrod pacjentow leczonych z powodu wybranych schorzen przewleklych [Prevalence of non-adherence to medication among patients treated for selected chronic conditions]. Pol Merkur Lekarski. 2011; 31: 215220. (in Polish).
  • 14
    Khanna R, Pace PF, Mahabaleshwarkar R, Basak RS, Datar M, Banahan BF. Medication adherence among recipients with chronic diseases enrolled in a state Medicaid program. Popul Health Manag. 2012; 15: 253260.
  • 15
    Britten N. Patients’ ideas about medicines: A qualitative study in a general practice population. Br J Gen Pract. 1994; 44: 454468.
  • 16
    Donovan JL, Blake DR. Patient non-compliance: Deviance or reasoned decision-making? Soc Sci Med. 1992; 34: 507513.
  • 17
    Fried TR, Tinetti ME, Towle V, O'Leary JR, Iannone L. Effects of benefits and harms on older persons’ willingness to take medication for primary cardiovascular prevention. Arch Intern Med. 2011; 171: 923928.
  • 18
    Steel N. Thresholds for taking antihypertensive drugs in different professional and lay groups: Questionnaire survey. BMJ. 2000; 320: 14461447.
  • 19
    Marshall T, Bryan S, Gill P, Greenfield S, Gutridge K, Birmingham Patient Preferences Group. Predictors of patients’ preferences for treatments to prevent heart disease. Heart. 2006; 92: 16511655.
  • 20
    Pound P, Britten N, Morgan M et al. Resisting medicines: A synthesis of qualitative studies of medicine taking. Soc Sci Med. 2005; 61: 133155.
  • 21
    Laerum E, Johnsen N, Smith P, Larsen S. Can myocardial infarction induce positive changes in family relationships? Fam Pract. 1987; 4: 302305.
  • 22
    Laerum E, Johnsen N, Smith P and Larsen S. Myocardial infarction may induce positive changes in life-style and in the quality of life. Scand J Prim Health Care. 1988; 6: 6771.
  • 23
    Collins RL, Taylor SE, Skokan LA. A better world or a shattered vision? Changes in life perspectives following victimization. Soc Cogn. 1990; 8: 263285.
  • 24
    Petrie KJ, Buick DL, Weinman J, Booth RJ. Positive effects of illness reported by myocardial infarction and breast cancer patients. J Psychosom Res. 1999; 47: 537543.
  • 25
    Rosenstock IM. Why people use health services. Milbank Mem Fund Q. 1966; 44: 94127.
  • 26
    Rosenstock IM, Strecher VJ, Becker MH. Social learning theory and the health belief model. Health Educ Behav. 1988; 15: 175183.